(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 26 May 2005 (26.05.2005)

PCT

(10) International Publication Number WO 2005/047336 A1

(51) International Patent Classification⁷: C07K 19/00

(21) International Application Number:

PCT/KR2004/002944

(22) International Filing Date:

13 November 2004 (13.11.2004)

(25) Filing Language:

Korean

(26) Publication Language:

English

(**30**) Priority Data: 10-2003-0080299

13 November 2003 (13.11.2003) KR

- (71) Applicant (for all designated States except US): HANMI PHARM. IND. CO., LTD. [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-813 (KR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KIM, Young, Min [KR/KR]; #102-803, Woonam dreamvalley, Gomae-ri, Giheung-eup, Yongi-si, Gyeonggi-do 449-901 (KR). KIM, Dae, Jin [KR/KR]; #28-402, Gubanpo Apt., Banpobon-dong, Seocho-gu, Seoul 137-049 (KR). BAE, Sung, Min [KR/KR]; #1360-24 (401), Seocho2-dong, Seocho-gu, Seoul 137-072 (KR). LIM, Chang, Ki [KR/KR]; #325-1706, Samic Apt., Yeongtong-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-470 (KR). KWON, Se, Chang [KR/KR]; #1002-2103, Hyundai 10-cha Apt., Gwangjang-dong, Gwangjin-gu, Seoul

143-210 (KR). LEE, Gwan, Sun [KR/KR]; #3-404, Woochang Apt., Ogeum-dong, Songpa-gu, Seoul 138-739 (KR).


- (74) Agent: SON, Min; 19th Floor, City Air Tower, 159-9 Samsung-dong, Gangnam-gu, Seoul 135-973 (KR).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROTEIN COMPLEX USING IMMUNOGLOBULIN FRAGMENT ANDMETHOD FOR THE PREPARATION THEREOF



(57) Abstract: Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, non-peptide polymer and immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.